Arena Pharmaceuticals Inc (ARNA.A) Quote| Reuters.com
Edition:
United States

Arena Pharmaceuticals Inc (ARNA.A)

ARNA.A on American Stock Exchange

1.65USD
27 Jun 2016
Change (% chg)

-- (--)
Prev Close
$1.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
13,829
52-wk High
$5.08
52-wk Low
$1.30

ARNA.A

Chart for ARNA.A

About

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management, and is... (more)

Overall

Beta: -0.50
Market Cap(Mil.): $401.02
Shares Outstanding(Mil.): 243.04
Dividend: --
Yield (%): --

Financials

  ARNA.A Industry Sector
P/E (TTM): -- 38.36 34.67
EPS (TTM): -0.43 -- --
ROI: -43.96 -6.77 14.11
ROE: -126.41 -6.10 15.33

BRIEF-Arena Pharmaceuticals Inc announces appointment of Kevin Lind as CFO

* Arena Pharmaceuticals Inc says Kevin R. Lind will join its management team as executive vice president and chief financial officer, effective June 15 Source text for Eikon: Further company coverage:

Jun 15 2016

BRIEF-Arena Pharmaceuticals files for mixed shelf of up to $250 mln

* Arena Pharmaceuticals Inc files for mixed shelf of up to $250 million - SEC filing Source text - (http://1.usa.gov/1tpehJq) Further company coverage:

Jun 14 2016

BRIEF-Arena Pharmaceuticals names Amit Munshi CEO

* Arena Pharmaceuticals announces appointment of Amit D. Munshi as President and Chief Executive Officer Source text for Eikon: Further company coverage:

May 09 2016

BRIEF-Arena Pharmaceuticals Q1 loss per share $0.09

* Arena pharmaceuticals reports first quarter 2016 financial results and provides corporate update

May 09 2016

BRIEF-Arena Pharmaceuticals reports favorable results from Phase 1B clinical trial of APD371

* Arena Pharmaceuticals reports favorable results from Phase 1B multiple-ascending dose clinical trial of APD371

Apr 12 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.